uniQure N.V. 8-K

What Happened

• On April 30, 2026, uniQure N.V. announced it held a pre-submission meeting with the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) regarding AMT-130, its investigational gene therapy for Huntington’s disease. The company plans to submit a Marketing Authorization Application (MAA) for AMT-130 in the third quarter of 2026. The announcement was made via press release and furnished in the company’s Form 8-K.

Key Details

• Date of filing/announcement: April 30, 2026 (Form 8-K).
• Therapy: AMT-130, an investigational gene therapy for Huntington’s disease.
• Regulatory step: Pre-submission meeting with the UK MHRA.
• Planned regulatory action: Submit Marketing Authorization Application (MAA) in Q3 2026.

Why It Matters

• This filing confirms a concrete regulatory timetable: uniQure is advancing AMT-130 from clinical/regulatory interactions toward a formal MAA submission. For investors, an MAA submission is a key milestone that can lead to regulatory review and potential approval, which would be material for the company’s future commercial prospects in treating Huntington’s disease. The announcement signals progress in uniQure’s development and regulatory strategy without promising specific outcomes or timelines beyond the planned Q3 2026 submission.